The next key catalyst is the PDUFA date on October 24, 2026. Monitor for any FDA advisory committee briefing documents or pre-meeting communications between now and then. The separate sNDA for lower-weight patients (planned H2 2026) adds a second catalyst. The prior CRL and resubmission process introduces some residual regulatory risk, but acceptance indicates the FDA views the package as substantially complete.
Price Chart
Executive Summary
Pharming announced FDA acceptance of its resubmitted sNDA for Joenja (leniolisib) to treat children aged 4-11 with APDS, with a PDUFA date of October 24, 2026. The resubmission follows a prior Complete Response Letter (CRL) in January 2026 and addresses FDA requests on analytical methods. If approved, Joenja would be the first U.S. treatment for pediatric APDS, expanding the addressable patient population and bolstering the product's lifecycle.
Key Facts
- FDA accepted resubmitted sNDA for Joenja in children aged 4-11 with APDS
- PDUFA target action date: October 24, 2026
- Resubmission follows Complete Response Letter (Jan 30, 2026) and Type A meeting (Mar 26, 2026)
- Seeks approval for 40 mg and 50 mg twice-daily dosing for patients weighing ≥27 kg
- Separate sNDA for lower-weight pediatric patients (<27 kg) planned for second half 2026
- Phase III data showed improvements in lymphadenopathy and naïve B cells over 12 weeks with no drug-related serious adverse events
- Joenja already approved for patients 12+ in the U.S. (March 2023), U.K., Australia, Israel, and Japan (4+)
Financial Impact
If approved, Joenja's pediatric label expansion could meaningfully broaden the treatable APDS population (1-2 per million), adding incremental revenue beyond the current adult/adolescent indication. No financial terms or revenue figures were disclosed in the filing.
Risk Factors
- FDA could issue a second CRL on or before the PDUFA date despite acceptance of the resubmission
- The separate sNDA for lower-weight patients has not yet been filed and may face its own regulatory hurdles
- Joenja faces potential competition from other PI3K inhibitors in development for APDS
- Commercial uptake in the pediatric population depends on diagnosis rates and payer coverage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001828316-26-000031 |
| Document: 0001828316-26-000031-index-headers.html | 0001828316-26-000031 |
| Document: 0001828316-26-000031-index.html | 0001828316-26-000031 |
| Document: 0001828316-26-000031.txt | 0001828316-26-000031 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 6-K | $11.21 $10.55 | ▼ −5.89% | ▼ −5.67% | $9.75 (−13.02%) |
Aug 13, 2026 7w ago | 6-K | $12.35 $11.68 | ▼ −5.43% | ▼ −3.46% | $9.75 (−21.05%) |
Jun 4, 2026 17w ago | 6-K | $12.47 $12.88 | ▲ +3.29% | ▲ +5.84% | $9.75 (−21.81%) |
May 28, 2026 18w ago | 6-K | $13.66 $12.24 | ▼ −10.40% | ▼ −10.35% | $9.75 (−28.62%) |
May 22, 2026 19w ago | 6-K | $13.62 $12.28 | ▼ −9.84% | ▼ −11.05% | $9.75 (−28.41%) |
Apr 16, 2026 24w ago | 6-K | $17.33 $16.64 | ▼ −3.98% | ▼ −4.97% | $9.75 (−43.74%) |
Mar 27, 2026 27w ago | 6-K | $16.31 $16.50 | ▲ +1.16% | ▼ −2.70% | $9.75 (−40.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access